STERIS plc $STE Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC lifted its holdings in shares of STERIS plc (NYSE:STE) by 183.2% during the third quarter, Holdings Channel reports. The fund owned 44,233 shares of the medical equipment provider’s stock after purchasing an additional 28,616 shares during the quarter. Intech Investment Management LLC’s holdings in STERIS were worth $10,945,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of STE. Norges Bank purchased a new position in shares of STERIS during the 2nd quarter valued at approximately $289,132,000. Orbis Allan Gray Ltd raised its holdings in STERIS by 36.0% in the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after acquiring an additional 556,088 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in STERIS by 246.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock valued at $137,041,000 after acquiring an additional 393,970 shares during the last quarter. Invesco Ltd. boosted its stake in STERIS by 32.2% during the 2nd quarter. Invesco Ltd. now owns 1,220,699 shares of the medical equipment provider’s stock valued at $293,236,000 after acquiring an additional 297,076 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in STERIS by 305.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 330,907 shares of the medical equipment provider’s stock worth $81,880,000 after acquiring an additional 249,386 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

STE has been the topic of a number of recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Trading Up 1.1%

STERIS stock opened at $254.50 on Friday. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The firm’s 50-day moving average is $255.88 and its 200-day moving average is $251.60. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The company has a market cap of $24.96 billion, a P/E ratio of 35.50 and a beta of 1.03.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the prior year, the firm posted $2.32 earnings per share. The company’s revenue was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio is presently 35.15%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.